Question: Charles Heidelberger, cancer researcher, developed the drug Fluorouracil (5-FU) which is sold under what name?

Context articles: Herman Eisen
CMF (chemotherapy)
Ron Laskey
Said Sebti
Jane C. Wright
Virginia Livingston
Charles Heidelberger
Ting-Chao Chou
Zheng Cui
Fluorouracil

Herman Nathaniel Eisen (1918–2014) was an American immunologist and cancer researcher.
 He served on the faculty at New York University School of Medicine in the early 1950s, became the Chief of Dermatology at the Washington University School of Medicine in 1955, and was a founding member of the MIT Center for Cancer Research (now called the Koch Institute for Integrative Cancer Research).
 Eisen retired and assumed professor emeritus status in 1989, but continued to be active as a researcher; he was working on a manuscript the day he died in 2014.
Cyclophosphamide Methotrexate Fluorouracil (CMF) is a commonly used regimen of breast cancer chemotherapy that combines three anti-cancer agents: cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU).
Ronald Alfred Laskey CBE FRS (born 26 January 1945) is a British cell biologist and cancer researcher.
 He was the Charles Darwin Professor of Embryology at the University of Cambridge.
 In 1991, he co-founded the Wellcome Trust/Cancer Research Campaign Institute (now known as the Wellcome Trust/Cancer Research UK Gurdon Institute), along with five other senior scientists including Professor Sir John Gurdon.
 In 2001, he founded the Medical Research Council Cancer Cell Unit in 2001, and was Director of the Unit until 2010.
 Laskey is also a Fellow of Darwin College, Cambridge.
Said Sebti (Arabic: سيد سبتي‎ ‎ , (first name (] ) is an American cancer researcher who is Professor and Chairman of the Department of Drug Discovery at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fl.
 Sebti is noted for his work to rehabilitate the 'failed' cancer drug Triciribine, now under development at the pharmaceutical company Prescient Therapeutics (ASX: PTX).
 Sebti is currently Chief Scientific Officer at Prescient Therapeutics.
Jane Cooke Wright (also known as "Jane Jones") (November 30, 1919 – February 19, 2013) was a pioneering cancer researcher and surgeon noted for her contributions to chemotherapy.
 In particular, Wright is credited with developing the technique of using human tissue culture rather than laboratory mice to test the effects of potential drugs on cancer cells.
 She also pioneered the use of the drug methotrexate to treat breast cancer and skin cancer (mycosis fungoids).
Virginia Livingston (1906–1990) was an American physician and cancer researcher who advocated the unsupported theory that a specific species of bacteria she named "Progenitor cryptocides" was the primary cause of cancer in humans.
 Her theories about "P. cryptocides" have not been duplicated by researchers, and a clinical trial of her therapy did not show any efficacy in the treatment of cancer.
 The American Cancer Society, which did not support Livingston’s treatment protocol for cancer, categorically denied her theory of cancer origins.
Charles Heidelberger (December 23, 1920 – January 18, 1983) was a cancer researcher who developed and patented an anticancer drug called 5-Fluorouracil that remains widely used against cancers of the stomach, colon and breast.
 He was also director of basic research at the University of Southern California's Comprehensive Cancer Center.
 He received an American Cancer Society National Award in 1974.
 Heidelberger served on editorial boards of various scientific journals: "Cancer Research", "Molecular Pharmacology", "Biochemical Pharmacology", the "International Journal of Cancer", "In Vitro" , and the "Journal of Medicinal Chemistry".
Ting-Chao Chou (born 1938 in Taiwan, Chinese name: 周廷潮) is a Chinese American theoretical biologist, pharmacologist, cancer researcher and inventor.
 His 457 scientific articles have been cited in 26,292 papers in over 754 biomedical journals as of May 5, 2017.
[1] He derived the median-effect equation (MEE) from the physico-chemical principle of the mass-action law, and introduced the median-effect plot in 1976.
[2,3] With Paul Talalay of the Johns Hopkins University School of Medicine, he derived the combination index equation (CIE) for multiple drug effect interactions, and introduced the concept of combination index (CI) for quantitative definition of synergism (CI<1), additive effect (CI=1), and antagonism (CI>1) using computerized simulations.
[3] One original article in Advances in Enzyme Regulation 22:27-55, 1984 by Chou-Talalay on CI has been cited 3,637 times internationally in a broad spectrum of journals.
[1] Integration of MEE and CIE resulted in Econo-Green bioresearch and new drug development.
[4] This integrated theory and algorithms allow conducting small number of data points, conservation of laboratory animals and reducing the number of patients in clinical trials.
 Consequently, this allows saving time and cost and resources as well as increasing efficiency an effectiveness in medical, pharmaceutical research and new drug development.
[4] With colleagues, T.C. Chou is inventor/co-inventor of 40 U.S. Patents, mainly for anticancer agents.
[5]
Zheng Cui, MD PhD, is a biochemist currently serving as an Associate Professor of Pathology (Tumor Biology) at Wake Forest University.
 As an oncologist and a cancer researcher Cui has proposed the unique idea that certain individuals (estimated at 10% to 15% of the human population) naturally produce a special kind of white blood cell that contains an inherent resistance to cancer.
 This idea is extremely controversial within the cancer biology community.
 These white blood cells, in Cui's view, could potentially be extracted from donors and given to cancer victims, thus endowing them with cancer resistance.
 Cui's research seems to indicate that the resistance includes many types of cancer.
 Cui's research is based on experiments on mice.
 These experiments resulted in Cui being able to cure cancer in several otherwise terminally sick mice.
 Cui is proposing eventual experimentation of the technique on human subjects.
Fluorouracil (5-FU), sold under the brand name Adrucil among others, is a medication used to treat cancer.
 By injection into a vein it is used for colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer.
 As a cream it is used for actinic keratosis and basal cell carcinoma.